hypothyroidism: subclinical, manifest, eutirox, updated composition


In the current conditions, coronavirus infection is often the cause of the development of inflammatory and autoimmune diseases of the thyroid gland. One of these diseases can be subclinical hypothyroidism — the initial stage of development of manifest hypothyroidism. Signs of hypothyroidism include weight gain, edema, decreased mental activity, increased drowsiness, dry skin, bradycardia, cardiomyopathy, constipation, muscle cramps, and paraesthesia. Because SG is asymptomatic by definition, 25–50% of patients have slow but characteristic signs of hypothyroidism, manifested by disorders of many organs and systems. Unfortunately, in most cases, such clinical manifestations are assessed retrospectively after the detection of characteristic hormonal changes. The expediency of treating both subclinical hypothyroidism and manifest hypothyroidism is evaluated individually, especially for the elderly, depending on the level of Thyroid-Stimulating Hormone and the presence of comorbid pathology. Synthetic levothyroxine remains the drug of choice for all forms of hypothyroidism. The generally accepted starting dose of levothyroxine for adult 13 patients, according to the recommendations of ATA, is considered a dose of 1.6–1.8 mcg/kg of body weight. Eutirox is a drug that has a unique line of 6 dosages in increments of 25 mcg of Levothyroxine and now the drug has an updated composition that fully ensures the balanced functioning of the thyroid gland. The updated composition is completely bioequivalent to the previous composition with similar tolerability. The increased requirements for the composition of the active substance, which was achieved in the updated composition of Eutirox, has advantages for patients, since hormone fluctuations will be minimized and this will help to avoid the development of adverse clinical consequences.


Sajenko Ja. A. Diabet. Ozhyrinnja. Metabolichnyj syndrom 2020; 2: 55-65.

Leng O, Razvi S. Thyroid Res 2019; 12(2).

Gottwald-Hostalek U, Uhl W, Wolna P, Kahaly GJ. Curr Med Res Opin 2017; 33(2): 169-174.

Buldygina JuV, Shljahtych SL. Mizhnar Endokrynol Zhurn 2015; 6: 35-40.

Patel H, Stalcup A, Dansereau R, Sakr A. Zdorov’ja Ukrai'ny 2020; 3(51): 24-25.

Duntas LH. Adv Ther 2019; Suppl: 1-3.

Duntas LH, Jonklaas J. Ad. Ther 2019; 36(Suppl 2): 30-46.

Walker JN, Shillo P, Ibbotson V, et al. Eur J Endocrinol 2013; 168(6): 913-917.

Lividas S, Bouthou C, Androulakis I, et al. Thyroid 2018; 28: 1580-1586.

Biondi B, Cappola NR, Cooper DS. JAMA 2019; 322(2): 153-160.

Jonklaas J, Bianco AC, Bauer AJ, et al. Thyroid 2014; 24(12): 1670-1751.

Pearce SHS, Brabant G, Duntas LH, et al. ETJ 2013; 2: 215-228.




How to Cite

Kravchun, N., Dunaieva, I., & Kozakov, O. (2021). PERSONALIZED THYROID HYPOFUNCTION THERAPY STRATEGY. Problems of Endocrine Pathology, 77(3), 120-125.